Lakewood-Amedex Biotherapeutics Inc. (LABT)

Lakewood-Amedex Biotherapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

LABT Income Statement

Financials in millions usd. Fiscal year is January - December.

Millions usd. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	-	1.92	3.1
Research & Development	-	2.1	5.53
Other Operating Expenses	0	0.01	0.01
Operating Expenses	-	4.03	8.64
Operating Income	-3.92	-4.03	-8.64
Interest Expense (Income)	0.03	-0.14	-0.35
Other Expense (Income)	0.1	0.97	-0
Pretax Income	-3.96	-4.86	-8.28
Net Income	-4.06	-4.86	-8.28
Free Cash Flow	-2.26	-5.73	-6.82
EBITDA	-3.91	-4.94	-8.59
Depreciation & Amortization	0.12	0.05	0.04
EBIT	-4.03	-4.99	-8.63

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).